Milsaperidone is an atypical antipsychotic used to treat adults with schizophrenia and manic or mixed episodes associated with bipolar I disorder. Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo.
- Mechanism
- Curator reviewed · 1 reference
The mechanism of action of milsaperidone in the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults is unknown. However, the efficacy of milsaperidone in these conditions could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo. Milsaperidone has an in vitro receptor binding profile similar to iloperidone.
- Primary indication
- Milsaperidone is indicated for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.Curator reviewed · 2 structured indications
- Formula / weight
- C24H29FN2O4 · 428.504 g/mol (avg)
- First approval
- United States, 2026
- Code names
- P-88-8991, (-)- · VHX-896
- Brand names
Resolves to
SBKZGLWZGZQVHA-INIZCTEOSA-NSMILESCOC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)[C@H](C)OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Milsaperidone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account